

To: Cagen, Stuart Z SHLOIL-SHOIL-SHS <stuart.cagen@shell.com>; 'Russell White' <whiter@api.org>; 'michael.g.bird@exxonmobil.com' <michael.g.bird@exxonmobil.com>
From: Tsai, Shan P SHLOIL-SHS
</O=SHELL/OU=MSXSOC/CN=RECIPIENTS/CN=ST196949>
Cc: 'Bruce Jarnot' <jarnotb@api.org>
Bcc:
Received Date: 2006-11-15 15:38:48 GMT
Subject: RE: Shanghai Health Study - new budget estimate

I am on business this week and vacation next week. Will try to call Dr. Fu next week.

Shan

-----Original Message-----

From: Cagen, Stuart Z SHLOIL-SHOIL-SHS
Sent: Tuesday, November 14, 2006 12:15 AM
To: 'Russell White'; michael.g.bird@exxonmobil.com; Tsai, Shan P SHLOIL-SHS
Cc: Bruce Jarnot
Subject: RE: Shanghai Health Study - new budget estimate

Russ:

Have you contacted Dr. Fu for an estimate based on the assumption of case accrual until the end of 2007 ? I think Shan Tsai is the contact from the technical committee.

Shan: a possible request for you to call Dr. Fu as per the response from Russ

I have not yet heard from Otto.

Thanks

Stuart

Stuart Cagen, Ph.D.

Senior Toxicologist
Shell Health Services
One Shell Plaza
910 Louisiana Street
Houston, Texas 77002

Telephone: 1-713-241-1407
Fax: 1-713-241-3325
Mobile: 1-832-646-3987

email: stuart.cagen@shell.com

-----Original Message-----

From: Russell White [mailto:whiter@api.org]
Sent: Monday, November 13, 2006 2:57 PM
To: michael.g.bird@exxonmobil.com
Cc: Cagen, Stuart Z SHLOIL-SHOIL-SHS; Bruce Jarnot
Subject: RE: Shanghai Health Study - new budget estimate

API has a separate with Fudan for support of the case-control study.

I'm putting together a spreadsheet that will include the new data and estimates for all contracts.

-----Original Message-----

From: michael.g.bird@exxonmobil.com
[mailto:michael.g.bird@exxonmobil.com]
Sent: Monday, November 13, 2006 3:49 PM
To: Russell White
Cc: stuart.cagen@shell.com
Subject: Re: Shanghai Health Study - new budget estimate

Russ, I know that Stuart is working Otto Wong's needs, but I believe there was mention of some separate contract or support for Dr Fu ? If so is that part of Otto's contract or a separate EA activity ? Just want to make sure that everything is covered.
Michael

Michael G. Bird, PhD., DABT
Toxicology & Environmental Sciences Division, ExxonMobil Biomedical Sciences, Inc.
1545 Route 22 East
P.O. Box 971
Annandale, New Jersey 08801-0971
tel: 908 730 1060
fax: 908 730 1199
Email: michael.g.bird@exxonmobil.com

This document and all information contained within this electronic message may be privileged, confidential and exempt from disclosure under applicable law. It is intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution, or taking of any action in reliance on the contents of the electronically transmitted materials is prohibited.

"Russell

White"

<whiter@api.or

To

g>

<BenzConsort-OC@listserve.api.org>,
<BenzConsort-TC@listserve.api.org>

cc

11/13/06 02:57

PM

Subject

Shanghai Health Study - new budget
estimate

Greetings,

Some OC members have asked for an estimate of individual company costs base on Dr. Irons new budget estimates. Using the eleven shares formula (XOM and BP have 3 shares, Chevron and Shell have 2 shares, and ConocoPhillips has 1 share);

Finish study - \$5,759,864

1 share \$523,624

2 shares \$1,047,248

3 shares \$1,570,872

Finish study and transition lab - \$6,999,864

1 share \$636,351

2 shares \$1,272,703

3 shares \$1,909,054

Finish study, transition lab, and publish results - \$7,599,864

1 share \$690,897

2 shares \$1,381,793

3 shares \$2,072,690